DGAP-News: STADA AGM: Executive Board gives positive outlook – Supervisory Board confirmed

STADA Arzneimittel AG / AGM/EGM

10.06.2008 

Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

At STADA Arzneimittel AG's Annual General Meeting, which took place today,
on June 10, 2008, in Frankfurt, the Executive Board, in their remarks,
confirmed the Group’s positive outlook. In addition, Dr. Eckhard Brüggemann
was re-elected as Chairman of the Supervisory Board of STADA Arzneimittel
AG in a Supervisory Board meeting held directly after the AGM, after all
shareholder representatives in the Supervisory Board were confirmed in
office by the shareholders for another five years at the AGM. In addition,
Karl Hertle (employee representative) was again elected by the Supervisory
Board as Deputy Chairman of the Supervisory Board.

In the course of the AGM, STADA's Chairman of the Executive Board, Hartmut
Retzlaff, in his speech, at first elaborated on the fiscal year 2007, which
was the twelfth year in a row where STADA was able to reach record levels
in sales and earnings. Then Retzlaff reported in detail on the strategic
and operative alignment of the Group. Here, the Executive Board’s positive
outlook for the business development was confirmed – despite still
challenging conditions. Retzlaff summarized his comments with the following
words: 'The markets are becoming tougher, so are we.'

The AGM endorsed all proposals of the Executive Board and Supervisory
Board. Thus, a dividend of EUR 0.71 per common share – an increase of 15%
compared to the previous year – was approved. The total dividend payments
of EUR 41.6 million thus represent approx. 40% of net income.


The Executive Board and the Supervisory Board were confirmed with nearly
100% approval. With similar approval, all shareholder representatives in
the Supervisory Board, Dr. Martin Abend, Dr. Eckhard Brüggemann, Uwe E.
Flach, Dr. K. F. Arnold Hertzsch, Dieter Koch and Constantin Meyer, were
confirmed in office for further five years. The advance resolutions for the
purchase and disposal of own shares as well as for capital measures found
significantly sufficient majorities.

The wording of today’s speech of STADA’s Chairman of the Executive Board
Hartmut Retzlaff as well as the exact voting results for all points on the
agenda can be found at STADA’s website under www.stada.com/agm2008.


Further information: 
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2–18 / 
D - 61118 Bad Vilbel / Phone: +49 (0) 6101 603-113 / 
Fax: +49 (0) 6101 603-506 / E-Mail: communications@stada.de
Or visit us in the internet at www.stada.com.
DGAP 10.06.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       STADA Arzneimittel AG
              Stadastraße 2-18
              61118 Bad Vilbel
              Deutschland
Phone:        +49 (0)6101 603- 113
Fax:          +49 (0)6101 603- 506
E-mail:       communications@stada.de
Internet:     www.stada.de
ISIN:         DE0007251803, DE0007251845, 
WKN:          725180, 725184, 
Indices:      MDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf;
              Freiverkehr in Berlin, Hannover, Hamburg, München, Stuttgart
End of News                                     DGAP News-Service
---------------------------------------------------------------------------